The biodefense industry has reached a critical point in its evolution. To accelerate product development for biodefense-related diagnostics, therapeutics, and reagents, we urgently need biological consensus standards - which generally do not exist. These standards can have an impact on overall R&D productivity and quality as profound as any technological advance, a fact readily acknowledged by biodefense leaders.













